Gilead Sciences is set to join the T-cell engager space in an unusual – perhaps even unprecedented – deal arrangement that involves the pharma budgeting $1.675 billion upfront to buy Ouro Medicines and for Galapagos …
AI predicts liver cancer risk with “high accuracy”
A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.
